For the study, researchers conducted a series of experiments on a type of nematode worm in 2010. The team identified 185 compounds that inhibited MRSA’s ability to kill the worms. Researchers selected two of these chemical compounds to investigate further. The compounds worked against MRSA by attacking the protective lipid bilayer of its cells’ membrane. This mechanism differs from traditional antibiotics as these drugs work against bacteria by attacking its metabolic processes. The chemical compounds displayed significant efficacy when used to treat MRSA infections in mice.
“With further development and optimization, [these] synthetic [compounds] have the potential to become a new class of antimicrobials for the treatment of Gram-positive bacterial infections that are currently difficult to cure,” wrote the study’s authors.
More articles on infection control:
Heart attack patients with depression 54% more likely to be hospitalized
How Virginia Hospital Center is slashing C-section rates
Study: Infection-related risk of death drops by 50% for kidney transplant patients
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
